In the search for potential predictors of hyporesponsiveness to EPO, Ingresciotta et al. [28] observed patient sex, age, baseline hemoglobin value, baseline ESA dosage, type of ESA used, category of hospital discharge diagnosis within one year prior to baseline date, comorbidities present, CKD stage or type of tumor, concomitant pharmacotherapy, and laboratory values as predictors of ESA hyporesponsiveness, highlighting serum CRP and high levels of baseline hemoglobin to be associated with poor response to ESA therapy. This evidence concerns the gene EPO and neoplasm.